Physician profile
Ronald Grubb
NPI 1790751485
$2,492.39
in general payments reported to CMS, 2019-2025
29 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $296 · 2021: $364 · 2022: $126 · 2023: $562 · 2024: $340 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $356.41 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $286.97 | 2021-2024 | |
| Abbott Laboratories | $231.28 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Pfizer INC. | $211.78 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205.94 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $126.24 | 2019-2025 | Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.79 | 2021-2024 | Xifaxan |
| Lilly USA, LLC | $102.40 | 2019-2023 | Mounjaro |
| Novo Nordisk INC | $76.54 | 2020-2021 | |
| Allergan, INC. | $68.68 | 2020 | |
| Astellas Pharma US INC | $68.19 | 2023-2024 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.31 | 2019-2023 | |
| Exact Sciences Corporation | $61.83 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $58.33 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.12 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $56.05 | 2019-2025 | Repatha, Otezla |
| Horizon Therapeutics Plc | $48.75 | 2019-2020 | |
| Boston Scientific Corporation | $41.40 | 2019-2023 | Watchman Access System |
| Eisai INC. | $37.11 | 2020-2021 | |
| Curonix LLC | $24.09 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Shield Therapeutics INC | $23.06 | 2024 | |
| Integra Lifesciences Corporation | $22.29 | 2020 | |
| Xeris Pharmaceuticals, INC. | $22.29 | 2023 | Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $20.89 | 2023 | |
| Halozyme INC | $19.32 | 2023 | |
| Inari Medical, INC. | $19.00 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Phathom Pharmaceuticals, INC. | $18.03 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $17.66 | 2022 | |
| Ucb, INC. | $17.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Grubb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.